LIPOTYPE

Their core work

Lipotype is a Dresden-based lipidomics company that provides high-throughput lipid profiling and analysis services to biomedical research consortia. Their core capability is mass spectrometry-based lipidomics — quantifying hundreds of lipid species from biological samples to support biomarker discovery, disease mechanism research, and precision medicine. Across their H2020 portfolio, they serve as the dedicated omics/lipidomics partner in large health projects tackling diabetes, kidney disease, obesity, and lung disease. They translate complex lipid data into clinically meaningful insights for disease stratification and treatment optimization.

What they specialise in

How they've shifted over time

In their early H2020 period (2016-2017), Lipotype focused squarely on diabetes and related metabolic conditions — diabetic kidney disease biomarkers (BEAt-DKD), type 2 diabetes risk prediction (RHAPSODY), and lysosomal storage disease mechanisms (LysoMod). From 2020 onward, their scope broadened significantly into lung disease exposomics (REMEDIA), stem cell-derived insulin therapies (ISLET), and obesity phenotyping (SOPHIA). The trajectory shows a company expanding from a narrow diabetes-lipidomics niche into a broader platform for disease-agnostic lipid analytics, while maintaining metabolic disease as their anchor domain.

Lipotype is evolving from a diabetes-focused lipidomics provider into a versatile omics service partner applicable across multiple disease areas, making them increasingly attractive for diverse health consortia.

How they like to work

Lipotype operates exclusively as a specialist participant — never coordinating, always contributing targeted analytical expertise to large research consortia. With 113 unique partners across 23 countries from just 6 projects, they consistently join large, multi-national consortia (averaging ~19 partners per project). This pattern indicates a company valued as a reliable service provider that plugs into complex projects without requiring a leadership role, making them low-risk and easy to integrate into new consortia.

Lipotype has built an extensive network of 113 unique consortium partners across 23 countries through just six projects, indicating involvement in large pan-European health initiatives. Their network spans academic medical centers, pharmaceutical companies, and biotech firms across the EU health research ecosystem.

What sets them apart

Lipotype occupies a rare niche as a dedicated commercial lipidomics service provider in the EU research landscape. While many academic labs perform lipidomics, few private companies offer it as a standardized, scalable service — making Lipotype a go-to partner when consortia need reproducible lipid profiling at scale. Their Dresden base, SME status, and consistent track record across six major health projects make them an efficient, proven choice for any consortium needing omics analytical capacity without the overhead of a large corporate partner.

Highlights from their portfolio

• ISLET
  Largest single grant (EUR 759K) and most ambitious scope — applying omics quality control to stem cell-derived insulin therapies, representing Lipotype's move into advanced therapy medicinal products.
• REMEDIA
  Second-largest grant (EUR 731K) and a strategic expansion into lung disease and exposomics, demonstrating Lipotype's ability to apply lipidomics beyond their traditional metabolic disease focus.
• BEAt-DKD
  Long-running project (2016-2023) combining lipidomics with imaging biomarkers and clinical trials for diabetic kidney disease — showcases their core precision medicine capability.